Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib

Ratnakar Patti, Kiranmai Gumired, Pallu Reddanna, Leslie N. Sutton, Peter C. Phillips, C. Damodar Reddy

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

In this study the role of cyclooxygenase-2 (COX-2) in primitive neuroectodermal tumor (PNET) the most malignant brain tumors of childhood was investigated. COX-2 expression in human brain tumor biopsy samples (seven/seven) was about 6-8-fold higher than normal brain tissue and several PNET cell lines also express COX-2. The effect of selective COX-2 inhibitors, celecoxib and rofecoxib on the growth of two PNET cell lines (DAOY and PFSK) was determined. Celecoxib was more potent than rofecoxib in suppressing cell growth. Growth inhibition by celecoxib and rofecoxib was independent of Bcl-2 expression. Celecoxib suppressed the expression of Akt and activated the caspase-3 in DAOY and PFSK, whereas rofecoxib did not have such an effect.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalCancer Letters
Volume180
Issue number1
DOIs
StatePublished - 6 Jun 2002
Externally publishedYes

Keywords

  • Caspase-3
  • Celecoxib
  • Cyclooxygenases
  • Primitive neuroectodermal tumors
  • Rofecoxib

Fingerprint

Dive into the research topics of 'Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib'. Together they form a unique fingerprint.

Cite this